Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Of Increasing Doses Of Epirubicin And Docetaxel Plus Pegfilgrastim For Locally Advanced Or Inflammatory Breast Cancer

NCT00066443 is registered in ClinicalTrials.gov with NCIC Clinical Trials Group as lead sponsor.

NCT NCT00066443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00066443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Of Increasing Doses Of Epirubicin And Docetaxel Plus Pegfilgrastim For Locally Advanced Or Inflammatory Breast Cancer
Lead sponsor
NCIC Clinical Trials Group
Phase
Phase 1/2
Overall status
Completed
Start date
November 3, 2003
Completion date
January 16, 2014
Enrollment
93 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer